Biocryst Pharmaceuticals (BCRX) Share-based Compensation Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.47% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 47.06% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.79% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 281.05% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 92.83% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 5.49% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 61.54% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | 1,086.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,086.31% |
| Dec 31, 2025 | 671.50% |
| Sep 30, 2025 | 363.95% |
| Jun 30, 2025 | -96.46% |
| Mar 31, 2025 | -42.51% |
| Dec 31, 2024 | -94.45% |
| Dec 31, 2023 | 289.04% |
| Dec 31, 2022 | -12.54% |
| Sep 30, 2022 | -83.53% |
| Jun 30, 2022 | -83.57% |
| Mar 31, 2022 | 75.23% |
| Dec 31, 2021 | -544.03% |
| Sep 30, 2021 | 176.09% |
| Jun 30, 2021 | 1,731.31% |
| Mar 31, 2021 | 98.95% |
| Dec 31, 2020 | 59.63% |
| Sep 30, 2020 | -14.86% |
| Jun 30, 2020 | -88.77% |
| Mar 31, 2020 | -16.97% |
| Dec 31, 2019 | 58.69% |